Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms Trofinetide

          Marvel Announces First of Two Final Data Sets from Rett Syndrome Study: MB-204 Significantly Outperforms TrofinetideMarch 13, 2025 7:00 AM EDT | Source: Marvel Biosciences Corp.Calgary, Alberta--(Newsfile Corp. - March 13, 2025) - Marvel Biosciences Corp. (TSXV: MRVL) (OTCQB: MBCOF) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to share part of the final data from its preclinical Rett syndrome study conducted in collaboration wi ...